Features | Partner Sites | Information | LinkXpress
Sign In
BioConferenceLive
GLOBETECH PUBLISHING
JIB

Collaboration to Provide Clinical Trial Services in the United Kingdom for Study Data Capture, Processing, and Reporting

By BiotechDaily International staff writers
Posted on 25 Feb 2013
Merge Healthcare, Inc. (Chicago, IL, USA), a provider of clinical systems, announced that NorthWise Services (NWS; Sittingbourne, UK) has collaborated with Merge and selected eClinical OS (operating system) to gather, manage, and report on clinical trials data across all studies.

NWS is a specialist contract research organization (CRO) providing services in data management, statistics, and medical writing. Its services are complementary to the offerings of Merge, which has allowed a strong and active working partnership to develop.

“NWS has always supported products at the forefront of eClinical technology, but in the past this tended to be separated into different software tools for EDC, ePRO, IVR, etc.,” explained Dr. Philip North, managing director of NorthWise Services. “It is therefore very appealing now to be able to access a wide range of eClinical functions on a single web-based platform, with just one user login and password.”

Recognizing the potential benefits of eClinical OS in collecting, managing, and reporting clinical trials data across all stages, NWS has arranged to have its own eClinical OS-certified study builder, who can now build studies for clients using eClinical OS.

“We were pleased with how easy it was for our study builder to become qualified and certified in the use of eClinical OS,” continued Dr. North. “Merge provided NWS access to eClinical OS in a sandbox environment during the self-training process. Because of this, the qualification was quickly and entirely achieved, using only the extensive online training materials available within eClinical OS. The built-in training materials were intuitive and thorough. Our staff did not require any additional help from Merge—though that would have been available if needed.”

Cost transparency using eClinical OS’s self-service quoting tool was also a benefit to NWS. “The cost calculator tool has been very valuable,” added Dr. North. “Not only is Merge eClinical OS competitive in the eClinical marketplace, but this tool allows us to remain competitive when bidding on a new study with our sponsor clients.”

“With eClinical OS, NWS has deep visibility into the cost of its studies,” said Justin Dearborn, president of Merge Healthcare. “We designed a cost calculator into the system which allows our clients to generate their own quotes and create budget scenarios in real-time. This provides them with the decision support tools to balance options and costs.”

Merge eClinical OS provides end-to-end study support through a single, easy-to-use interface allowing clients to manage and run studies more effectively. It provides built-in study templates, libraries, and reports to help users create studies quickly and manage them effectively without technical, assistance. Merge eClinical OS works for the largest and smallest studies, has the flexibility to support trials in any phase, and captures any type of data, from any source, from any modality.

Merge’s enterprise and cloud-based systems for image intensive specialties provide access to any image, 24/7. Merge also provides health stations, clinical trials software and other health data and analytics solutions that engage consumers in their personal health.

NorthWise Services provides a range of services, including data management, statistics, and medical writing, to the biotechnology, pharmaceutical, and other industries, and other products and services through strategic working alliances.

Related Links:
Merge Healthcare
NorthWise Services


comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: In the liver tissue of obese animals with type II diabetes, unhealthy, fat-filled cells are prolific (small white cells, panel A). After chronic treatment through FGF1 injections, the liver cells successfully lose fat and absorb sugar from the bloodstream (small purple cells, panel B) and more closely resemble cells of normal, non-diabetic animals (Photo courtesy of the Salk Institute for Biological Studies).

Fibroblast Growth Factor 1 Treatment Restores Glucose Control in Mouse Diabetes Model

A "vaccine" based on the metabolic regulator fibroblast growth factor 1 (FGF1) removed the insulin resistance that characterizes type II diabetes and restored the body's natural ability to manage its glucose... Read more

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel
Image: This type of electronic pacemaker could become obsolete if induction of biological pacemaker cells by gene therapy proves successful (Photo courtesy of Wikimedia Commons).

Gene Therapy Induces Functional Pacemaker Cells in Pig Heart Failure Model

Cardiovascular disease researchers working with a porcine heart failure model have demonstrated the practicality of using gene therapy to replace implanted electronic pacemakers to regulate heartbeat.... Read more

Lab Technologies

view channel

Precise Ion Irradiation Dosing Method Developed for Cancer Therapy

Scientists are employing nuclear physics principles to provide more effective approaches to radiotherapy treatment for cancer patients. Radiation therapy using heavy ions is best suitable for cancer patients with tumors that are difficult to access, such as in the brain. These particles scarcely damage the penetrated... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.